CardioDx revives IPO plans with infusion of fresh leadership
CardioDx, the heart disease test developer that delayed plans to go public in November due to poor market conditions, has decided to test the IPO waters again. This time it will be doing it with some new leadership.
IMS Health stock jumps after second biggest U.S. IPO of 2014
The IPO was priced at $20 a share--above the midpoint of the range--and rose when trading began on Friday.
TriVascular Technologies to target $13-$15 per share as IPO terms become clear
TriVascular Techologies is setting the terms for its planned IPO, and the California maker of stent grafts to treat abdominal aortic aneurysms aims for a fairly robust debut.
Ariosa Diagnostics mulls an IPO worth up to $69M
Ariosa Diagnostics filed plans for an IPO worth as much as $69 million. The company said it will use the money, in part, to heighten commercialization efforts for its Harmony prenatal genetic test.
The first two days of trading passed uneventfully, with Circassia's stock fluctuating around the 310 pence ($5.20) per share price it commanded in the IPO to close on Wednesday at 309 pence.
TriVascular envisions a $100M IPO to propel AAA stent graft rollout
California's TriVascular Technologies is betting it can broaden the reach of its FDA-approved stent grafts to treat abdominal aortic aneurysms and has filed plans to raise up to $100 million in an IPO to help accomplish its goal.
The U.K.'s Lombard Medical details its $80M IPO plans
Lombard Medical is disclosing IPO details following its initial announcement in January. The U.K. maker of an aortic repair device said it plans to raise up to $80 million, and will trade on the Nasdaq under the symbol "EVAR," according to a regulatory filing.
U.K. blood Dx screener Quotient filed a proposed $75M IPO
Quotient, a U.K. company focused on blood transfusion diagnostics, unveiled plans for an initial public offering that would raise as much as $75 million. The move continues a steady trickle of IPO movement among testing companies that began late last fall.
Last year's M&A darling, Biomet files for an IPO
Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.
Buzz: BGI is preparing for a $400M Hong Kong IPO in Q4
It is months since the chatter around Chinese sequencing giant BGI's initial public offering advanced from "will it happen?" to "when, where and how much?" Now Bloomberg has some answers. A $400 million IPO in Hong Kong is reportedly penciled in for the fourth quarter.